SynAct Pharma Balance Sheet Health
Financial Health criteria checks 6/6
SynAct Pharma has a total shareholder equity of SEK169.2M and total debt of SEK0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are SEK217.1M and SEK48.0M respectively.
Key information
0%
Debt to equity ratio
SEK 0
Debt
| Interest coverage ratio | n/a |
| Cash | SEK 38.49m |
| Equity | SEK 169.16m |
| Total liabilities | SEK 47.97m |
| Total assets | SEK 217.13m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 8F8's short term assets (SEK63.5M) exceed its short term liabilities (SEK16.4M).
Long Term Liabilities: 8F8's short term assets (SEK63.5M) exceed its long term liabilities (SEK31.6M).
Debt to Equity History and Analysis
Debt Level: 8F8 is debt free.
Reducing Debt: 8F8 has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 8F8 has sufficient cash runway for 5 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: 8F8 is forecast to have sufficient cash runway for 5 months based on free cash flow estimates, but has since raised additional capital.